(Q37903140)

25 August 2017

1 reference

title

Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials (English)

1 reference

25 August 2017

0 references

María Grau

4

0 references

author name string

Jordi Ginés

1

1 reference

25 August 2017

Eliazar Sabater

2

1 reference

25 August 2017

Clara Martorell

3

1 reference

25 August 2017

Marta Monroy

5

1 reference

25 August 2017

Miguel A Casado

6

1 reference

25 August 2017

publication date

1 July 2011

1 reference

Clinical and Translational Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

issue

7

1 reference

25 August 2017

page(s)

485-498

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Taxanes in the adjuvant therapy of breastcancer with positive nodes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0686-X

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

21 January 2018

1 reference

12 December 2020

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

12 December 2020

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

12 December 2020

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

12 December 2020

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

1 reference

12 December 2020

Taxanes for adjuvant treatment of early breast cancer

1 reference

12 December 2020

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

12 December 2020

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

1 reference

12 December 2020

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

1 reference

12 December 2020

Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009

1 reference

12 December 2020

10.1007/S12094-011-0686-X

Identifiers

DOI

1 reference

25 August 2017

1 reference